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Summary
Background:	In	the	last	2	decades,	several	studies	have	examined	the	association	be-
tween	maternal	thyroid	hormone	insufficiency	during	pregnancy	and	neurodevelop-
mental	disorders	in	children	and	shown	conflicting	results.
Aim:	This	systematic	review	aimed	to	assess	the	evidence	for	an	association	between	
maternal	 thyroid	 hormone	 insufficiency	 during	 pregnancy	 and	neurodevelopmental	
disorders	in	children.	We	also	sought	to	assess	whether	levothyroxine	treatment	for	
maternal	thyroid	hormone	insufficiency	improves	child	neurodevelopment	outcomes.
Methods:	 We	 performed	 systematic	 literature	 searches	 in	 MEDLINE,	 EMBASE,	
PSYCinfo,	CINAHL,	AMED,	BNI,	Cochrane,	 Scopus,	Web	of	 Science,	GreyLit,	Grey	
Source	and	Open	Grey	(latest	search:	March	2017).	We	also	conducted	targeted	web	
searching	and	performed	forwards	and	backwards	citation	chasing.	Meta-	analyses	of	
eligible	studies	were	carried	out	using	the	random-	effects	model.
Results:	We	identified	39	eligible	articles	(37	observational	studies	and	2	randomized	
controlled	trials	[RCT]).	Meta-	analysis	showed	that	maternal	subclinical	hypothyroid-
ism	and	hypothyroxinaemia	are	associated	with	indicators	of	intellectual	disability	in	
offspring	(odds	ratio	[OR]	2.14,	95%	confidence	interval	[CI]	1.20	to	3.83,	P	=	.01,	and	
OR	1.63,	95%	CI	1.03	to	2.56,	P	=	.04,	respectively).	Maternal	subclinical	hypothyroid-
ism	and	hypothyroxinaemia	were	not	associated	with	attention	deficit	hyperactivity	
disorder,	and	their	effect	on	the	risk	of	autism	in	offspring	was	unclear.	Meta-	analysis	
of	RCTs	showed	no	evidence	that	levothyroxine	treatment	for	maternal	hypothyroxi-
naemia	or	subclinical	hypothyroidism	reduces	the	incidence	of	low	intelligence	quo-
tient	in	offspring.
Limitations:	Although	studies	were	generally	of	good	quality,	there	was	evidence	of	
heterogeneity	between	the	included	observational	studies	(I2	72%-	79%).
Conclusion:	Maternal	hypothyroxinaemia	and	subclinical	hypothyroidism	may	be	as-
sociated	with	 intellectual	disability	 in	offspring.	Currently,	 there	 is	no	evidence	that	
levothyroxine	treatment,	when	initiated	8-	to	20-	week	gestation	(mostly	between	12	
and	17	weeks),	for	mild	maternal	thyroid	hormone	insufficiency	during	pregnancy	re-
duces	intellectual	disability	in	offspring.
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution	License,	which	permits	use,	distribution	and	reproduction	in	any	medium,	
provided	the	original	work	is	properly	cited.
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1  | INTRODUCTION
Thyroid	hormone	is	essential	for	optimum	neurological	development	
of	the	foetus.	However,	the	foetal	thyroid	gland	is	not	functional	until	
the	12-	14th	week	of	gestation,1	and	during	that	period,	the	foetus	is	
solely	dependent	on	thyroxine	from	the	mother.	Therefore,	it	is	plau-
sible	that	maternal	thyroid	hormone	insufficiency,	particularly	in	early	
pregnancy,	 could	 impair	 foetal	neurodevelopment.	 Indeed,	 in	 recent	
years,	several	studies	have	shown	that	even	mild	maternal	thyroid	hor-
mone	insufficiency	(including	subclinical	hypothyroidism	and	isolated	
hypothyroxinaemia)	during	pregnancy	is	associated	with	various	types	
of	neurodevelopmental	disorders	in	children,	including	reduced	intel-
ligence	quotient	(IQ)	scores,2 autism3	and	attention	deficit	hyperactiv-
ity	disorder	(ADHD).4	However,	other	studies	have	shown	conflicting	
results,5,6	 and	 there	 remains	 an	 uncertainty	 whether	 levothyroxine	
treatment	 in	mild	maternal	 thyroid	 hormone	 insufficiency	 improves	
neurodevelopmental	outcomes	in	children.7	These	observations	have	
led	to	an	ongoing	debate	about	whether	all	pregnant	women	should	
be	screened	and	treated	for	thyroid	dysfunction.
We	 therefore	 conducted	 a	 systematic	 review	 and	meta-	analysis	
to	assess	 the	evidence	 for	an	association	between	maternal	 thyroid	
hormone	insufficiency	during	pregnancy	and	neurodevelopmental	dis-
orders	in	childhood,	with	a	focus	on	intellectual	disability,	autism	spec-
trum	disorders	and	ADHD,	which	show	substantial	comorbidity.8	We	
also	assessed	the	evidence	from	randomized	controlled	trials	(RCTs)	of	
the	effects	of	levothyroxine	treatment	in	pregnant	mothers	with	thy-
roid	hormone	insufficiency	on	child	neurodevelopmental	outcomes.
2  | METHODS
A	 systematic	 review	was	 conducted	 according	 to	 the	 best	 practice	
guidelines	recommended	by	the	Centre	for	Research	Dissemination9 
and	 is	 reported	 in	 accordance	 with	 the	 PRISMA	 reporting	 guide-
lines.10	A	predefined	protocol	was	developed	and	 is	 registered	with	
PROSPERO	(2016:	CRD42016032790).
2.1 | Literature search
A	comprehensive	search	syntax	using	MeSH	and	free	text	terms	was	
developed	 for	 MEDLINE	 (Appendix	 S1)	 and	 adapted	 as	 appropri-
ate	 for	 the	 other	 searched	 databases:	 EMBASE,	 PsycInfo,	 CINAHL,	
AMED,	 the	British	Nursing	 Index,	 the	Cochrane	Central	Register	of	
Controlled	Trials,	Scopus,	Web	of	Science,	GreyLit,	Grey	Source	and	
Open	Grey	(WT).	MEDLINE,	EMBASE	and	PsychInfo	were	searched	
using	OVID;	CINAHL	 and	AMED	were	 searched	using	 EBSCOhost;	
the	British	Nursing	Index	was	searched	using	ProQuest;	the	Cochrane	
central	Register	of	Controlled	Trials	was	searched	using	Wiley;	Scopus	
was	searched	using	Elsevier;	and	Web	of	Science	was	searched	using	
Thomson-	Reuters	platforms.	All	databases	were	searched	from	incep-
tion	 to	 February	 2016,	with	 an	 update	 search	 conducted	 in	March	
2017.	 No	 study	 design	 or	 language	 restrictions	 were	 imposed,	 but	
case-	reports,	case-	series,	reviews,	editorials	and	commentaries	were	
excluded.
The	 search	 strategy	 consisted	of	3	blocks	of	 terms,	 those	 for	 (i)	
hypothyroidism,	 (ii)	 neurodevelopmental	 disorders	 and	 (iii)	 mothers	
and	pregnancy.	Terms	for	neurodevelopmental	disorders	were	taken	
from	the	4th	and	5th	edition	of	the	Diagnostic	and	Statistical	Manual	
for	Mental	Disorders	(DSM-	IV	and	DSM5)11	with	additional	terminol-
ogy	 from	 the	 International	 Classifications	 of	 Diseases	 10th	 edition	
(ICD-	10).12
The	“Research”	section	of	the	websites	of	the	following	organiza-
tions	was	reviewed	(March	2016)	in	detail	for	additional	publications:	
Autistica,	 Autism	 Speaks,	 Dame	 Shirley	 Foundation,	 International	
Society	 for	Autism	Research,	 Simons	 Foundation,	Waterloo	 founda-
tion,	 National	 Autistic	 Society,	 British	 Thyroid	 Foundation,	 British	
Thyroid	 Association,	 Society	 for	 Endocrinology	 and	 the	 American	
Thyroid	Association.	Forwards	(using	Scopus)	and	backwards	citation	
searching	was	used	to	identify	additional	relevant	papers.
2.2 | Eligibility criteria
Observational	 studies	 were	 included	 if	 they	 investigated	 the	 asso-
ciation	 of	 maternal	 thyroid	 hormone	 insufficiency	 (including	 overt	
hypothyroidism,	 subclinical	 hypothyroidism	 and	 maternal	 hypothy-
roxinaemia)	 in	mothers	 during	 pregnancy	with	 neurodevelopmental	
outcomes	in	their	children.	Overt	hypothyroidism	was	defined	as	high	
serum	thyroid-	stimulating	hormone	(TSH)	levels	and	low-	serum-	free	
thyroxine	(fT4)	or	total	thyroxine	(tT4),	subclinical	hypothyroidism	as	
high	TSH	levels	with	normal	fT4	or	tT4	levels	and	hypothyroxinaemia	
as	 normal	 TSH	with	 low	 fT4	 or	 tT4	 levels.	 Studies	measuring	 TSH,	
fT4	and	tT4	as	continuous	variables	were	also	included.	Studies	were	
classified	as	indicating	intellectual	disability	where	IQ,	language	delay	
or	global	developmental	delay	was	measured,	and	were	classified	as	
ADHD	or	 autism	 studies	where	 a	diagnosis	or	 a	 validated	 scale	 for	
measuring	 these	 conditions	were	 reported	 as	 an	 outcome	measure	
in	the	offspring.	We	excluded	studies	that	focussed	on	psychomotor	
development	 rather	 than	 neuropsychological	 development.	 Studies	
were	 included	 if	 the	children	studied	were	between	0	and	18	years	
old.	RCTs	were	included	if	they	studied	pregnant	women	with	thyroid	
hormone	insufficiency,	and	randomly	assigned	them	to	treatment	with	
levothyroxine	or	to	a	control	group	and	reported	children’s	neurode-
velopmental	outcomes.
Only	studies	published	after	1994	were	 included	 in	the	analysis,	
coinciding	with	the	publication	of	DSM-	IV	which	introduced	changes	
in	terminology	used	to	describe	neurodevelopmental	outcomes.
K E Y W O R D S
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2.3 | Study selection
The	 search	 results	 were	 uploaded	 to	 reference	 management	 soft-
ware	(Endnote	X7).	Titles	and	abstracts	were	screened	for	relevance	
independently	 by	 2	 reviewers	 (WT	 and	 JTC	 or	GB),	with	 any	 disa-
greements	being	 resolved	by	discussion	 and	 involvement	of	 a	 third	
reviewer	(JTC	or	GB)	where	necessary.	The	full	text	of	potentially	rel-
evant	papers	was	retrieved	and	screened	in	the	same	way	using	the	
prespecified	inclusion	and	exclusion	criteria.	All	duplicate	papers	were	
double-	checked	and	excluded.	“Sibling”	papers	derived	from	the	same	
parent	study	were	identified	and	linked.
2.4 | Data collection
For	each	study,	data	on	study	and	participant	characteristics,	inter-
vention/exposure,	thyroid	status	and	relevant	neurodevelopmental	
outcomes	were	extracted	by	1	reviewer	(WT)	into	a	bespoke	data	
extraction	form,	which	was	piloted	on	a	random	sample	of	studies	
and	refined.	All	data	extraction	was	checked	by	a	second	reviewer	
(JTC	or	GB)	with	discrepancies	resolved	by	discussion	and	involve-
ment	of	a	third	reviewer	(JTC	or	GB)	where	necessary.	Authors	were	
contacted	to	provide	clarification	or	additional	data	if	necessary.
2.5 | Quality assessment
The	quality	of	 the	design	and	 reporting	of	 included	studies	was	as-
sessed	using	the	Downs	and	Black	checklist13	by	1	reviewer	(WT)	and	
checked	by	a	second	(JTC	or	GB),	a	reliable	and	valid	quality	index	for	
the	appraisal	of	both	RCTs	and	nonrandomized	studies.	Discrepancies	
were	resolved	through	discussion	and	involvement	of	a	third	reviewer	
(JTC	or	GB)	where	necessary.
2.6 | Data analysis
Studies	were	tabulated	and	described	narratively	in	the	first	instance.	
Studies	were	only	included	in	the	meta-	analysis	with	the	following	cri-
teria:	(i)	they	used	a	fixed	predictor,	(ii)	that	the	fixed	predictor	used	was	
at	 a	 threshold	of	 clinical	 relevance,	 (iii)	 that	 they	provided	numerical	
data	and	(iv)	used	an	outcome	assessment	that	was	well	known	and	val-
idated.	Where	meta-	analysis	was	possible,	 the	 following	prespecified	
principles	were	applied	to	the	data	prior	to	analysis:	(i)	for	studies	using	
multiple	tests	for	the	same	outcome,	the	most	commonly	used	test	was	
reported,	(ii)	where	available,	the	total	test	score	was	used	rather	than	
subscales,	(iii)	where	a	trait	was	measured	over	multiple	time	periods,	
the	latest	point	of	measuring	would	be	chosen,	as	neurodevelopmen-
tal	 traits	 at	 an	older	 age	 tend	 to	be	more	 stable,	 (iv)	where	multiple	
cut-	offs	of	TSH	and	fT4	were	measured,	the	most	extreme	cut-	off	was	
used	and	when	an	outcome	was	measured	both	against	a	continuous	
thyroid	hormone	measure	and	against	a	cut-	off	value	(eg	cut-	off	of	the	
10th	percentile	fT4	for	hypothyroxinaemia)	the	cut-	off	value	was	used,	
(v)	where	 thyroid	hormone	 samples	were	 collected	at	multiple	 times	
in	pregnancy,	the	earliest	time	was	chosen	as	hypothyroidism	in	early	
pregnancy	is	believed	to	be	more	problematic	than	in	later	pregnancy,	
(vi)	where	both	fT4	and	tT4	were	measured,	the	value	for	fT4	was	used	
and	(vii)	adjusted	measures	were	used	when	provided.
Where	possible,	continuous	results	 including	those	derived	from	
regression	coefficients	were	converted	to	odds	ratios	using	the	method	
described	by	Chinn	and	colleagues.14,15	Continuous	results	were	also	
converted	to	odds	ratios	using	the	method	described	by	Suissa16 and 
Whitehead17	and	explored	the	impact	of	the	conversion	method	used	
in	sensitivity	analyses.	Meta-	analyses	were	also	performed	using	stud-
ies	only	reporting	odds	ratios.	We	also	carried	out	sensitivity	analysis	
(post	hoc)	by	carrying	out	meta-	analyses	where	the	results	were	split	
by	the	point	in	gestation	when	maternal	thyroid	hormones	were	mea-
sured,	to	test	the	potential	adverse	effects	of	thyroid	dysfunction	in	
early	pregnancy	vs	late	pregnancy.
Some	studies	gave	results	that	were	split	by	a	covariate,	which	
were	 not	 comparable	with	 other	 studies.	Data	 from	 the	 study	 re-
ported	by	Päkkilä	et	al18	for	ADHD,	for	example,	were	split	by	gen-
der,	hence	the	authors	were	contacted	for	results	for	both	genders	
combined.
Meta-	analysis	 was	 conducted	 using	 STATA	 using	 the	 random-	
effects	model.
3  | RESULTS
3.1 | Search results
In	total,	39	original	articles	were	found	to	be	eligible	for	this	system-
atic	review,	with	37	observational	studies	and	2	RCTs2,3,5-7,18-51	(Table	
S1).	Overall	909	176	people	participated	in	these	studies	(857	014	of	
them	being	from	one	study37).	A	flow	diagram	summarizing	search	re-
sults	is	shown	in	Figure	1.
3.2 | Risk of bias and heterogeneity
Observational	studies	have	an	inherent	risk	of	selection	bias	and	con-
founding.	Quality	assessment	using	the	Downs	and	Black	checklist13 
(Table	S2)	showed	that	some	of	these	studies	also	had	noticeable	risk	
of	bias	relating	to	attrition	bias	(Table	S3).	One	study	had	a	high	risk	of	
bias,	as	it	had	inadequate	information	on	participant	demographics.23 
One	 of	 the	 RCTs7	was	 not	 placebo-	controlled	 and	 suffered	 from	 a	
high	attrition	rate	(Table	S4).
There	was	variation	between	the	included	studies	in	terms	of	tim-
ing	of	the	assessment	of	thyroid	function	during	pregnancy,	definitions	
of	thyroid	dysfunction	and	child	age	at	the	time	of	assessment	of	neu-
rodevelopment	outcome	measures	(Table	S1).
3.3 | Observational studies excluded from  
meta- analysis
In	total,	26	studies	(24	observational	studies	and	both	RCTs)	were	in-
cluded	in	the	meta-	analysis.	Five	studies	presenting	regression	analy-
ses	were	excluded26,29,30,35,45	because	they	did	not	provide	regression	
information	 in	 a	 form	 that	 would	 allow	 straightforward	 conversion	
into	odds	ratios:	for	example,	2	studies29,30	provided	linear	regression	
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results	with	continuous	not	binary	predictors.	A	further	8	articles	were	
excluded	from	the	meta-	analysis	for	the	following	reasons:	sibling	pa-
pers	with	no	additional	data	(n	=	2),21,51	lacking	numerical	data	(n	=	1),44 
using	a	novel	outcome	measure	that	was	not	validated	or	suitable	for	
meta-	analysis	(n	=	1),34	reporting	odds	ratios	(using	logistic	regression)	
but	 using	 continuous	predictors	 (n	=	1)39	 and	 reporting	psychomotor	
outcomes	 only	 (n	=	3).19,24,42	 Details	 on	 why	 studies	 were	 excluded	
from	the	meta-	analysis	are	shown	in	Table	S5.
3.4 | Association between maternal thyroid hormone 
insufficiency and indicators of intellectual disability
3.4.1 | Overt hypothyroidism
There	were	 inadequate	 data	 to	 perform	 a	meta-	analysis	 on	 the	 asso-
ciation	between	overt	hypothyroidism	and	indicators	of	intellectual	dis-
ability.	Two	studies	claimed	to	measure	overt	hypothyroidism,2,48 but in 
F IGURE  1 The	PRISMA	diagram	showing	search	strategy	and	exclusion	criteria	at	each	step
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practice,	the	exposed	groups	in	these	studies	consisted	of	a	mixture	of	
overt	and	subclinical	hypothyroidism	cases	as	the	hypothyroidism	diag-
nosis	was	based	entirely	on	TSH	levels	rather	than	TSH	and	fT4 combined.
3.4.2 | Subclinical hypothyroidism
Eleven	 studies	were	 included	 in	 the	meta-	analysis	 (Figure	2).	There	
was	evidence	of	an	effect	of	maternal	subclinical	hypothyroidism	on	
the	risk	of	 intellectual	 impairment	 in	children	(odds	ratio	[OR]	2.14,	
95%	confidence	interval	[CI]	1.20	to	3.83,	P	=	.01).	Haddow	et	al2 and 
Päkkilä	et	al48	had	some	cases	of	overt	hypothyroidism	within	the	ex-
posed	group,	though	removal	of	these	studies	made	no	difference	to	
the	significance	of	the	result	(OR	2.33,	95%	CI	1.12	to	4.87,	P	=	.02)	
(Figure	S1).	When	only	studies	reporting	odds	ratios	directly	(6	stud-
ies)	were	included	in	the	meta-	analysis,	maternal	subclinical	hypothy-
roidism	was	not	significantly	associated	with	indicators	of	intellectual	
disability,	though	the	magnitude	of	the	point	estimate	was	similar	(OR	
2.37,	95%	CI	0.96	to	5.85)	(Table	S6).	When	only	studies	(n	=	4)	that	
measured	TSH	before	12	weeks	were	included	in	the	meta-	analysis,	
maternal	subclinical	hypothyroidism	was	not	significantly	associated	
with	 indicators	 of	 intellectual	 disability,	 and	 the	 magnitude	 of	 the	
point	estimate	was	 reduced	 (OR	1.11,	95%	CI	0.66	 to	1.88,	P	=	.7)	
(Figure	S5).	The	5	studies	are	not	included	in	the	subclinical	hypothy-
roidism	 and	 risk	 of	 intellectual	 impairment	meta-	analysis26,27,29,35,39 
found	 no	 association	 between	maternal	 subclinical	 hypothyroidism	
and	impaired	neuropsychological	development	in	children.
3.4.3 | Hypothyroxinaemia
Eleven	 studies	 were	 included	 in	 the	 meta-	analysis	 (Figure	3).	
Compared	to	those	children	born	to	euthyroid	mothers,	children	born	
to	mothers	with	hypothyroxinaemia	were	significantly	more	likely	to	
show	signs	of	intellectual	impairment	(OR	1.63,	95%	CI	1.03	to	2.56,	
P	=	.04).	The	3	studies	excluded	from	the	hypothyroxinaemia	and	risk	
of	intellectual	impairment	meta-	analysis26,29,35	found	no	association	
between	maternal	 hypothyroxinaemia	 and	 impaired	 neurodevelop-
ment	 in	children.	Our	sensitivity	analyses	showed	that	 the	method	
used	 to	 convert	 continuous	measures	 to	 odds	 ratios	 had	 little	 im-
pact	on	interpretation	(Table	S6).	When	only	studies	reporting	odds	
ratios	 (4	 studies)	were	 included	 in	 the	meta-	analysis,	maternal	 hy-
pothyroxinaemia	was	not	significantly	associated	with	 indicators	of	
intellectual	 disability,	 though	 the	 magnitude	 of	 the	 point	 estimate	
was	 similar	 (OR	2.11,	 95%	CI	0.92	 to	4.83)	 (Table	 S6).	When	only	
studies	(n	=	4)	that	measured	fT4	before	12	weeks	were	included	in	
the	meta-	analysis,	maternal	hypothyroxinaemia	was	not	significantly	
associated	with	indicators	of	intellectual	disability,	though	the	magni-
tude	of	the	point	estimate	was	similar	(OR	1.22,	95%	CI	0.55	to	2.74,	
P	=	.62)	(Figure	S6).
3.5 | Association between maternal thyroid hormone 
insufficiency and autism
Three	studies	investigated	the	link	between	maternal	overt	hypothy-
roidism	 and	 autism,	 3	 studies	 investigated	 the	 link	 between	mater-
nal	subclinical	hypothyroidism	and	autism,	and	2	studies	investigated	
the	 link	between	maternal	hypothyroxinaemia	and	autism.	Of	 the	3	
studies	 that	 investigated	 the	 link	between	maternal	 overt	 hypothy-
roidism	and	autism,	2	studies37,50	are	based	on	overt	hypothyroidism	
status	on	hospital	records,	whilst	one	study40	measured	the	mother’s	
thyroid	 hormones	 directly.	 As	 there	was	 no	 information	 on	 thyroid	
hormone	 levels	on	 the	mothers	with	hypothyroidism	based	on	hos-
pital	 records,37,50	we	 analysed	 the	 results	 from	 these	 studies	 sepa-
rately	from	the	study	with	the	direct	thyroid	hormone	measurement	in	
participants.40	There	was	no	statistically	significant	effect	of	maternal	
overt	hypothyroidism	based	on	hospital	records	on	autism	in	children	
(OR	2.12,	95%	CI	0.75	to	6.00,	P	=	.12)	(Figure	S2).	The	one	study	that	
F IGURE  2 Meta-	analysis	of	studies	on	
association between maternal subclinical 
hypothyroidism	and	indicators	of	
intellectual	disability	in	offspring.	ES,	Odds	
ratio	point	estimate;	negative	association,	
trait	associated	with	decreased	odds	of	
neurodevelopmental	impairment;	positive	
association,	trait	associated	with	increased	
odds	of	neurodevelopmental	impairment
NOTE: Weights are from random-effects analysis
Overall  (I2 = 72.2%, P = .000)
Pakkila (2015)
Noten (2015)
Murphy (2015)
Williams (2012)
Su (2011)
Li (2010)
Chen (2015)
Study
Haddow (1999)
Smit (2000)
Williams (2013)
Behrooz (2011)
2.14 (1.20, 3.83)
1.05 (0.55, 2.02)
0.72 (0.44, 1.17)
2.53 (1.01, 6.34)
3.70 (1.80, 7.61)
10.49 (1.01, 119.19)
15.63 (4.70, 51.99)
1.65 (0.52, 5.22)
ES (95% CI)
3.00 (1.00, 8.00)
1.47 (0.15, 13.99)
1.28 (0.21, 7.90)
1.15 (0.36, 3.66)
100.00
12.27
13.15
10.65
11.85
%
4.21
8.95
9.24
Weight
9.90
4.55
5.99
9.22
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measured	thyroid	hormones	directly40	found	no	association	between	
maternal	overt	hypothyroidism	and	autism.	Of	the	3	studies	that	in-
vestigated	the	link	between	maternal	subclinical	hypothyroidism	and	
autism,3,39,40	2	used	continuous	predictors3,39	and	were	excluded	from	
meta-	analysis,	 thus	no	meta-	analysis	 could	 take	place.	None	of	 the	
3	 studies3,39,40	 found	 a	 positive	 association	 between	maternal	 sub-
clinical	hypothyroidism	and	autism.	Of	the	2	studies	that	investigated	
the	association	between	maternal	hypothyroxinaemia	and	autism,3,40 
one	used	a	continuous	predictor40	thus	was	excluded,	thus	no	meta-	
analysis	could	 take	place.	The	study	 that	used	a	continuous	predic-
tor40	found	no	association	between	maternal	hypothyroxinaemia	and	
autism,	whilst	the	one	that	used	a	binary	predictor3	did.	Therefore,	the	
effect	of	maternal	thyroid	hormone	insufficiency	on	the	risk	of	autism	
in	the	offspring	is	unclear.
3.6 | Association between maternal 
hypothyroidism and ADHD
One	 study	 investigated	 the	 link	 between	 maternal	 overt	 hypothy-
roidism	and	ADHD,	5	studies	investigated	the	link	between	maternal	
subclinical	hypothyroidism	and	ADHD	(2	were	included	in	the	meta-	
analysis),	and	5	studies	investigated	the	link	between	maternal	hypo-
thyroxinaemia	and	ADHD	(2	were	included	in	the	meta-	analysis).	The	
one	study	that	investigated	the	link	between	maternal	overt	hypothy-
roidism	and	ADHD	in	children	found	no	significant	association	(hazard	
ratio	1.10,	 95%	CI	0.98	 to	1.25).37	Our	meta-	analysis	 found	no	 as-
sociation	between	maternal	subclinical	hypothyroidism	and	ADHD	in	
children	(OR	1.58,	95%	CI	0.5	to	5.0,	P	=	.44)	(Figure	S3)	or	between	
maternal	 hypothyroxinaemia	 and	ADHD	 in	 children	 (OR	 1.34,	 95%	
F IGURE  4 Meta-	analysis	of	RCTs	on	
the	effect	of	levothyroxine	treatment	for	
maternal	subclinical	hypothyroidism	and	
hypothyroxinaemia	on	IQ	of	offspring.	
ES,	Odds	ratio	point	estimate;	negative	
association,	trait	associated	with	decreased	
odds	of	neurodevelopmental	impairment;	
positive	association,	trait	associated	with	
increased	odds	of	neurodevelopmental	
impairment
NOTE: Weights are from random-effects analysis
.
.
Overall  (I2 = 0.0%, P = .865)
Subtotal  (I 2 = 0.0%, P = .937)
Casey (2017)
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Subclinical Hypothyroidism
Lazarus (2012)
Maternal Hypothyroxinaemia
Casey (2017)
Subtotal  (I 2 = 0.0%, P = .449)
Lazarus (2012)
0.92 (0.76, 1.11)
0.88 (0.67, 1.17)
1.00 (0.75, 1.33)
ES (95% CI)
0.90 (0.51, 1.58)
0.88 (0.63, 1.21)
0.95 (0.74, 1.23)
0.78 (0.44, 1.39)
100.00
45.48
43.93
Weight
11.34
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%
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intellectual	disability	in	offspring.	ES,	Odds	
ratio	point	estimate;	negative	association,	
trait	associated	with	decreased	odds	of	
neurodevelopmental	impairment;	positive	
association,	trait	associated	with	increased	
odds	of	neurodevelopmental	impairment
NOTE: Weights are from random-effects analysis
Overall  (I2 = 78.9%, P = .000)
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CI	0.17	to	10.47,	P	=	.78)	 (Figure	S4).	Of	the	3	studies	not	 included	
in	meta-	analysis,	2	studies29,45	 found	no	association	between	either	
subclinical	hypothyroidism	or	hypothyroxinaemia	and	ADHD,	whilst	
one study30	found	an	association	between	high	TSH	and	externalizing	
symptoms.
3.7 | Effect of levothyroxine treatment in maternal 
thyroid hormone insufficiency on neurodevelopment 
outcomes in children
We	identified	2	RCTs	that	reported	the	effects	of	treatment	of	ma-
ternal	thyroid	hormone	insufficiency	with	levothyroxine	on	the	inci-
dence	of	 low	 IQ.	Compared	 to	 children	 born	 to	 untreated	mothers	
with	subclinical	hypothyroidism,	there	was	no	significant	difference	in	
IQ	levels	in	children	born	to	such	mothers	treated	with	levothyroxine	
(OR	0.95,	95%	CI	0.74	to	1.23,	P	=	.71)	(Figure	4).	Likewise,	there	was	
also	no	significant	difference	in	IQ	levels	in	children	born	to	mothers	
with	 hypothyroxinaemia	 treated	with	 levothyroxine	 and	 those	who	
were	not	treated	(OR	0.88,	95%	CI	0.67	to	1.17,	P	=	.38)	(Figure	4).
4  | DISCUSSION
This	 systematic	 review	 and	 meta-	analysis	 show	 an	 association	 be-
tween	 maternal	 subclinical	 hypothyroidism	 and	 hypothyroxinaemia	
during	pregnancy	and	 indicators	of	 intellectual	disability.	There	was	
no	association	between	maternal	thyroid	hormone	insufficiency	and	
the	risk	of	ADHD	in	offspring,	and	the	effect	of	maternal	thyroid	hor-
mone	insufficiency	on	the	risk	of	autism	in	the	offspring	was	unclear.	
We	also	found	no	evidence	that	levothyroxine	treatment	of	mothers	
with	 subclinical	 hypothyroidism	 or	 hypothyroxinaemia	 during	 preg-
nancy	reduces	the	incidence	of	low	IQ	in	children,	although	the	num-
ber	of	studies	with	data	able	to	contribute	to	this	was	small	(n	=	2).
During	the	course	of	our	study,	2	systematic	reviews	with	meta-	
analyses	 on	 the	 association	 between	 maternal	 thyroid	 hormone	
insufficiency	 and	 neurodevelopmental	 disorders	 in	 offspring	 were	
published.52,53	Compared	 to	 these	 previous	 systematic	 reviews,	 our	
study	had	a	wider	scope	as	we	analysed	multiple	neurodevelopmen-
tal	 disorders	 (including	 autism	 and	ADHD)	 in	 addition	 to	 indicators	
of	 intellectual	 disability,	 and	 performed	 meta-	analysis	 on	 RCTs	 of	
levothyroxine	 treatment	 for	pregnant	women	with	mild	 thyroid	hor-
mone	insufficiency	to	improve	neurological	outcomes	in	offspring.	We	
searched	9	mainstream	databases	(as	well	as	3	grey	literature	bases),	
as	compared	to	2	databases	searched	by	Wang	et	al53	and	3	databases	
search	by	Fan	et	al,52	thus	finding	more	eligible	studies	and	increasing	
confidence	that	we	have	identified	all	available	relevant	evidence.	Our	
finding	of	the	association	between	maternal	subclinical	hypothyroid-
ism	and	hypothyroxinaemia	with	indicators	of	intellectual	disability	in	
offspring	is	consistent	with	the	results	of	the	previous	meta-	analyses,	
although	our	result	did	show	a	smaller	magnitude	of	an	effect.52,53	Our	
meta-	analysis	included	more	studies	per	meta-	analysis	than	the	pre-
vious	 systematic	 reviews,52,53	 for	 example,	 Fan	 and	 colleagues52 in-
cluded	only	2	studies	in	their	subclinical	hypothyroidism	meta-	analysis	
compared	 to	 the	11	studies	 included	 in	our	meta-	analysis.	Wang	et	
al53	did	not	assess	 the	association	between	subclinical	hypothyroid-
ism	and	 indicators	of	 intellectual	 disability.	 In	 a	previous	 systematic	
review,	Chan	and	Boelaert54	analysed	the	effects	of	subclinical	hypo-
thyroidism	and	hypothyroxinaemia	on	obstetric	outcomes;	however,	
the	 study	 did	 not	 include	meta-	analysis	 of	 child	 neurodevelopment	
outcomes.
The	 association	 between	 mild	 maternal	 thyroid	 hormone	 insuf-
ficiency	 (subclinical	 hypothyroidism	 and	 hypothyroxinaemia)	 and	
neurodevelopment	 in	 offspring	 found	 in	 this	 systematic	 review	 is	
biologically	 plausible.	 Thyroid	 hormones	 have	 an	 important	 impact	
at	various	 stages	of	 foetal	 neurological	 development,	 including	pro-
liferation	and	differentiation	of	neuronal	precursors,	neuronal	migra-
tion and myelination.55	FT3,	the	active	form	of	thyroxine,	plays	a	key	
role	 in	the	process	of	neuronal	migration	 in	the	brain	by	stimulating	
brain	 cells	 (particularly	Cajal-	Retzius	 cells	 in	 the	 cerebellum)	 to	pro-
duce	Reelin,	which	in	turn	acts	as	a	scaffold	for	migrating	neurons.55 
This	is	a	major	part	in	the	formation	of	the	cerebellum,56	the	corpus	
callosum57	and	the	cerebral	cortex,55	areas	 in	 the	brain	 that	are	 im-
portant	in	motor58,59	and	cognitive	function.60	Thyroid	hormone	is	also	
important	 in	 the	process	of	white	matter	 formation,	 stimulating	 the	
secretion	 of	 proteins	 relevant	 to	myelination.61	Thus,	mild	maternal	
thyroid	hormone	insufficiency	could	influence	neurodevelopment	via	
these	mechanisms.	Indeed,	recent	imaging	studies	have	demonstrated	
structural	changes	in	different	parts	of	the	brain	in	children	of	women	
with	thyroid	hormone	insufficiency	in	pregnancy.44,62-64	Interestingly,	
the	effect	of	thyroxine	on	neuronal	migration	is	largely	influenced	by	
the	α-	thyroid	hormone	receptor,	which	is	expressed	throughout	foetal	
development,	whilst	myelination	is	largely	influenced	by	the	β-	thyroid	
hormone	 receptor	which	 is	 expressed	much	 later	 in	development.65 
Even	 though	maternal	 thyroid	hormone	 insufficiency	 in	early	gesta-
tion	(before	the	foetal	thyroid	gland	becomes	functional)	is	potentially	
likely	 to	 have	more	 deleterious	 effect	 on	 foetal	 neurodevelopment,	
our	sensitivity	analyses	of	the	studies	 in	which	thyroid	function	was	
measured	before	12	weeks	failed	to	show	an	association	between	ma-
ternal	subclinical	hypothyroidism	or	hypothyroxinaemia	and	indicators	
of	intellectual	disability.	The	explanation	for	this	observation	is	unclear	
but	may	be	due	to	smaller	sample	sizes.
This	 systematic	 review	 found	 no	 association	 between	 maternal	
thyroid	hormone	 insufficiency	 and	offspring	 risk	of	ADHD	while	 its	
impact	on	the	offspring	risk	of	autism	was	unclear.	As	some	research-
ers	have	suggested	autism	appears	to	be	linked	to	a	lack	of	neuronal	
migration,66	 and	 some	 studies	 suggest	ADHD	 is	 linked	 to	 a	 lack	 of	
functional	connectivity67	(hinting	at	a	lack	of	white	matter	formation),	
it	 seems	 possible	 that	 hypothyroxinaemia	 in	 early	 pregnancy	 could	
lead	to	autism	whilst	hypothyroxinaemia	in	later	pregnancy	could	lead	
to	ADHD.	As	most	of	the	studies	measured	fT4	between	the	first	and	
second	trimesters,	this	could	explain	the	lack	of	an	association	found	
between	maternal	thyroid	hormone	insufficiency	and	ADHD.	Future	
studies	should	explore	the	effects	of	maternal	thyroid	hormone	insuf-
ficiency	at	different	stages	of	pregnancy.
We	were	 unable	 to	 demonstrate	 evidence	 of	 a	 beneficial	 effect	
of	 levothyroxine	 treatment	 in	 pregnant	 women	 with	 mild	 thyroid	
582  |     THOMPSON eT al.
hormone	insufficiency	on	neurodevelopmental	outcomes	in	offspring.	
Considering	that	at	an	observational	level	both	maternal	hypothyrox-
inaemia	and	subclinical	hypothyroidism	were	associated	with	indicators	
of	intellectual	disability,	this	result	is	surprising.	It	could	be	that	the	in-
tervention was delivered too late in gestation (average gestational age 
at	recruitment:	Lazarus	et	al7	~12	weeks,	Casey	et	al49	~17	weeks)	for	
it	to	have	a	meaningful	effect;	however,	both	studies	performed	sensi-
tivity	analysis	on	when	in	pregnancy	the	intervention	was	delivered	and	
found	no	different	result.	It	is	also	possible	that	the	studies	measured	
the	IQ	of	the	children	at	too	young	an	age	(Lazarus	et	al7	at	3	years,	
Casey	et	al49	at	5	years),	considering	 that	 the	original	Haddow	et	al2 
study	measured	IQ	at	8	years.	Furthermore,	there	is	a	possibility	that	
the	association	between	hypothyroxinaemia	and	indicators	of	intellec-
tual	disability	seen	in	the	observational	studies	is	mediated	by	iodine	
deficiency,68	 and	 thus	 not	 completely	 ameliorated	 by	 levothyroxine.	
Finally,	it	is	also	possible	that	the	RCTs	were	not	big	enough	to	see	an	
effect.	Therefore,	further	large	RCTs	with	intervention	earlier	in	preg-
nancy	and	longer	follow-	up	of	children	are	needed	to	resolve	this	issue.
The	current	guideline	from	the	American	Thyroid	Association	rec-
ommends	levothyroxine	treatment	for	pregnant	women	with	subclin-
ical	hypothyroidism	in	the	presence	of	thyroid	peroxidase	antibodies	
or	serum	TSH	greater	 than	10	mIU/L	but	not	 for	maternal	hypothy-
roxinaemia.69	 In	 contrast,	 the	 guideline	 from	 the	 European	 Thyroid	
Association	recommends	treating	maternal	subclinical	hypothyroidism	
as	well	as	maternal	hypothyroxinaemia,	the	latter	if	diagnosed	during	
the	first	trimester.70	Neither	Association	has	recommended	universal	
screening	for	subclinical	hypothyroidism	or	maternal	hypothyroxinae-
mia	during	pregnancy,	owing	to	a	lack	of	robust	evidence	for	the	bene-
fit	from	screening	and	treating	mild	thyroid	hormone	insufficiency.69,70 
The	findings	of	this	systematic	review	support	the	Associations’	rec-
ommendations	and	support	the	guideline	from	the	American	Thyroid	
Association	on	not	treating	isolated	maternal	hypothyroxinaemia.	This	
systematic	 review	does	not	 support	 the	Associations’	 recommenda-
tions69,70	of	treating	maternal	subclinical	hypothyroidism	in	pregnancy	
to	prevent	 low	 IQ;	 however,	 clinicians	may	wish	 to	 treat	 subclinical	
hypothyroidism	in	pregnancy	to	prevent	other	adverse	obstetric	out-
comes	like	miscarriage	and	premature	birth.71
This	study	has	several	limitations.	Firstly,	there	was	heterogene-
ity	between	the	studies,	in	terms	of	study	population	(together	with	
differential	iodine	status	of	the	populations),	gestational	age	at	the	
time	of	thyroid	dysfunction,	different	definitions	of	thyroid	dysfunc-
tion,	whether	or	not	patients	on	thyroxine	included	in	the	cohort,	age	
of	offspring	at	the	time	of	neuropsychological	assessment	and	mea-
sures	of	neurodevelopmental	disorders	(Table	S1).	There	are	also	the	
inherent	problems	linked	to	observational	studies,	which	formed	the	
majority	of	the	studies	analysed,	such	as	selection	bias.	Secondly,	it	
was	difficult	to	categorize	the	type	of	thyroid	hormone	insufficiency	
for	some	studies.	For	example,	studies	 reported	by	Haddow	et	al2 
and	Päkkilä	et	al48	classified	thyroid	dysfunction	based	on	TSH	lev-
els	 rather	 than	 the	combination	of	TSH	and	 fT4	 levels.	Therefore,	
although	we	 included	 these	as	 subclinical	hypothyroidism	studies,	
it	 is	possible	that	a	small	number	of	subjects	with	high	TSH	 levels	
had	 overt	 hypothyroidism.	However,	 sensitivity	 analyses	 in	which	
we	removed	these	studies	did	not	change	the	overall	results	of	the	
meta-	analysis.	Likewise,	in	the	RCT	reported	by	Lazarus	et	al,7	23	of	
the	mothers	in	the	hypothyroxinaemia	group	also	had	both	elevated	
TSH	 levels	 in	 addition	 to	 low	 fT4	 levels,	 thus	 constituting	 overt	
hypothyroidism,	 though	 they	were	 in	 the	minority	 and	unlikely	 to	
have	impacted	on	the	overall	results.	Thirdly,	5	observational	stud-
ies	also	explicitly	included	participants	being	treated	with	levothy-
roxine	 for	 hypothyroidism	within	 the	 case	 group,2,5,23,37,50	making	
the	 direct	 comparison	with	 other	 studies	where	 the	 treatment	 of	
participants	is	unclear	difficult.	Also,	different	studies	had	different	
exclusion	criteria,	 for	example	2	studies	only	 included	participants	
with	 known	 thyroid	 disease,5,20	 whilst	 others	 explicitly	 excluded	
participants	with	known	thyroid	disease.28,32	Finally,	several	studies	
report	thyroid	function	as	continuous	outcomes	rather	than	dichot-
omous.	Where	possible,	we	converted	results	from	such	studies	into	
odds	ratios	using	2	different	methods,14-17	and	there	was	no	differ-
ence	 in	 interpretation	between	 the	2	 results	generated.	However,	
we		excluded	5	studies	from	meta-	analysis	as	it	was	not	possible	to	
	convert	their	results	to	odds	ratios.
In	 conclusion,	 our	 systematic	 review	 and	meta-	analysis	 showed	
an	association	between	mild	maternal	thyroid	hormone	insufficiency	
(subclinical	hypothyroidism	and	hypothyroxinaemia)	in	pregnancy	and	
impaired	neuropsychological	development	in	offspring.	We	found	no	
evidence	that	levothyroxine	treatment	for	maternal	mild	thyroid	hor-
mone	 insufficiency,	 including	maternal	 hypothyroxinaemia	 and	 sub-
clinical	 hypothyroidism,	 improves	 neurodevelopmental	 outcomes	 in	
children.
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